跳至主要内容
临床试验/EUCTR2014-002796-28-NL
EUCTR2014-002796-28-NL进行中(未招募)不适用

The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers. - CEASE STIFFNESS

niversity Medical Center Groningen (UMCG)0 个研究点开始时间: 2015年4月23日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 18 years or older
  • Systemic sclerosis based on the 2013 ACR/EULAR criteria
  • Raynaud’s phenomenon (RP)
  • A history of digital ulcer disease
  • Assessable Pulse Wave Velocity (PWV) measurement at baseline
  • Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Hypersensitivity to the active substance or to any of the excipients
  • Moderate to severe hepatic impairment, i.e., Child-Pugh class B or C
  • Baseline values of liver aminotransferases, i.e., aspartate
  • aminotransferases (AST) and/or alanine aminotransferases (ALT), greater
  • than 3 times the upper limit of normal
  • Concomitant use of cyclosporine A
  • Pregnancy
  • Women of child-bearing potential who are not using reliable methods of
  • contraception
  • Significant peripheral vascular disease as the sole consequence of
  • atherosclerotic disease due to for example diabetes, dyslipidemia,
  • systemic hypertension, coagulopathy

研究者

发起方
niversity Medical Center Groningen (UMCG)

相似试验